Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Data Supports Singlera's PanSeer Test as Company Narrows Focus to Colorectal Cancer Detection

Data Supports Singlera's PanSeer Test as Company Narrows Focus to Colorectal Cancer Detection

Jul 31, 2020
|
Molika Ashford
Premium

NEW YORK – Cancer early detection firm Singlera is pushing forward to commercialize a DNA-methylation-based assay called PanSeer with an immediate focus on colorectal cancer, but potential to expand that to a more pan-cancer setting in the future.

The company, which was founded in 2014 and has offices in California and Shanghai, reached a milestone this month with the publication of promising data from a study of the assay's performance in a longitudinal cohort of cancer-free individuals — the intended use population for this type of screening test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

Cell Studies on SARS-CoV-2 Spike Variant, Host Transcriptomes, Glioma-Infiltrating T Cells

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Molecular Diagnostics

  1. Walgreens to Sell Labcorp COVID-19 PCR Home Collection Kits Over-the-Counter

  2. WuXi Diagnostics Closes $150M Series B Financing Round

  3. NeoGenomics Q4 Revenue Grows 18 Percent, CEO to Retire

  4. Myriad Genetics Quarterly Revenues Decline 21 Percent

  5. ACMG Lobbying State Legislatures on Genetic Counselors' Scope of Practice Draws Criticism

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.